Back
Full-text
Journal article

Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM.

  • Giovannoni G Queen Mary University London, UK.
  • Gold R St Josef Hospital, Ruhr University, Germany.
  • Kappos L University Hospital, Basel Neurology, Switzerland.
  • Arnold DL Montreal Neurological Institute, McGill University, Canada.
  • Bar-Or A Montreal Neurological Institute, McGill University, Canada.
  • Marantz JL Biogen, USA.
  • Yang M
  • Lee A
Show more…
  • 2017-06-14
Published in:
  • Multiple sclerosis journal - experimental, translational and clinical. - 2016
Delayed-release dimethyl fumarate
Multiple Sclerosis Functional Composite
disability evaluation
disease progression
multiple sclerosis
neuropsychological tests
English The effect of delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) on the Multiple Sclerosis Functional Composite (MSFC) was assessed using integrated Phase 3 DEFINE and CONFIRM data. Patients treated with DMF (n = 769) demonstrated significant superiority on the MSFC, and each component, compared with placebo (n = 771) over two years: mean change for DMF vs placebo was 0.054 vs -0.053 on MSFC; -0.088 vs -0.286 on Timed 25-Foot Walk, 0.047 vs 0.003 on 9-Hole Peg Test and 0.178 vs 0.123 on Paced Auditory Serial Addition Test. DMF was an efficacious treatment for patients with MS.
Language
  • English
Open access status
gold
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/2804
Statistics
Document views: 20 File downloads:
  • Full-text: 0